DoD Neurofibromatosis Clinical Consortium Award

Post Date

May 6th 2016

Application Due Date

August 1st 2016

Funding Opportunity Number

W81XWH-16-NFRP-CCA

CFDA Number(s)

12.420

Funding Instrument Type(s)

Cooperative Agreement
Grant

Funding Activity Categories

Science and Technology and other Research and Development

Number of Awards

1

Eligibility Categories

Unrestricted

Funding

• Estimated Total Funding:

  $5000000

• Award Range:

  $None - $None

Grant Description

The FY16 NFRP Clinical Consortium Award is intended to support a major goal/product-driven Consortium of exceptional institutions and investigators that will accelerate the clinical translation of basic NF research and ultimately decrease the impact of the disease. The objectives of the Consortium shall be to conceive, design, develop, and conduct collaborative Phase I and II clinical evaluations of promising therapeutic agents for the management or treatment of NF1, NF2, and schwannomatosis. The NF Clinical Consortium needs to be a collaboration of multiple organizations and individuals for the purpose of rapidly executing clinical trials. The Consortium must consist of a single Operations Center and a minimum of five Clinical Trial Sites with a demonstrated history of collaborative research. The participants will be jointly responsible for prioritizing, proposing, conducting, and analyzing Phase I and Phase II clinical trials focused on therapeutic interventions for NF1, NF2, and schwannomatosis. The Operations Center and associated Clinical Trial Sites must apply to this announcement through a single application submitted by the Operations Center. The Operations Center may also serve as a trial site. A single award will be made to the Operations Center. Award funds are to be used to support the Operations Centerмs efforts as well as Consortium-associated studies at through the appropriate subcontract or other instruments for the Clinical Trial Sites. Award selection will be based on evaluation of the proposed plans for initial clinical trials to be implemented, available capabilities, organization of the Consortium, and feasibility of the collective group to accomplish the overall award objectives (see Section III.B., Application Review Process). During the performance period of the award, the Operations Center and all Clinical Trial Sites will be responsible for working collaboratively to identify new clinical trials for implementation by the Consortium. The NFRP is allocating a total of $9M in support of the Consortium. The Consortium will be funded initially for a total of $5M with allocations from the FY16 NFRP Congressional appropriation. Two additional option periods, to be included in the application, will be funded for a total of $2M each (minimum of 1 trial per option must be proposed), subject to receipt of future Congressional appropriations. See Section I.D., Funding, for additional information.

Contact Information

• Agency

  Department of Defense

• Office:

  Dept. of the Army -- USAMRAA

• Agency Contact:

  CDMRP Help Desk
  Phone: 301-682-5507
  Email: help@eBRAP.org

• Agency Mailing Address:

  CDMRP Help Desk

• Agency Email Address:

  help@eBRAP.org